Trial Profile
Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Brilaroxazine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms RECOVER
- Sponsors Reviva Pharmaceuticals
- 15 Apr 2024 According to a Reviva Pharmaceuticals media release, the company expect to have completed all of the outlined NDA submission requirements by the third quarter of 2025.
- 28 Mar 2024 According to a Reviva Pharmaceuticals media release, data will be presented at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.
- 26 Mar 2024 According to a Reviva Pharmaceuticals media release, data from this trial will be presented at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting, to be held in Colorado Springs, CO, USA on March 27-29, 2023.